POPULARITY
7 episodes with honorary consultant
2 episodes with honorary consultant
2 episodes with honorary consultant
2 episodes with honorary consultant
2 episodes with honorary consultant
2 episodes with honorary consultant
2 episodes with honorary consultant
2 episodes with honorary consultant
In this episode Martin talks to Dr Andy Borman, (Acting Head and Consultant Clinical Scientist, UKHSA National UK Mycology Reference Lab. also Hon Professor of Medical Mycology, MRC CMM, University of Exeter), Dr Colin Brown (Deputy Director of Emerging and Epidemic Infections at UK Health Security Agency; Honorary Consultant in Infectious Diseases & Medical Microbiology at Royal Free London NHS Foundation Trust) and Dr Mariyam Mirfenderesky (Consultant in Medical Microbiology and Infectious Diseases North Middlesex and RF (AMS Lead) and UKHSA on HCAI). The UK Health Security Agency (UKHSA) is the national organisation in the United Kingdom responsible for protecting public health by preventing, detecting, and responding to infectious diseases and other health threats. We chat about how Candidozyma auris (formerly known as Candida auris) is identified in the lab, why it matters clinically, and what it means for infection prevention and control teams. From early lab detection to real-world frontline challenges, we discuss the key issues around this emerging pathogen — and what we need to do next. UK C. auris guidance can be found here: https://www.gov.uk/government/publications/candida-auris-laboratory-investigation-management-and-infection-prevention-and-control
In this episode Martin talks to Dr Andy Borman, (Acting Head and Consultant Clinical Scientist, UKHSA National UK Mycology Reference Lab. also Hon Professor of Medical Mycology, MRC CMM, University of Exeter), Dr Colin Brown (Deputy Director of Emerging and Epidemic Infections at UK Health Security Agency; Honorary Consultant in Infectious Diseases & Medical Microbiology at Royal Free London NHS Foundation Trust) and Dr Mariyam Mirfenderesky (Consultant in Medical Microbiology and Infectious Diseases North Middlesex and RF (AMS Lead) and UKHSA on HCAI). The UK Health Security Agency (UKHSA) is the national organisation in the United Kingdom responsible for protecting public health by preventing, detecting, and responding to infectious diseases and other health threats. We chat about how Candidozyma auris (formerly known as Candida auris) is identified in the lab, why it matters clinically, and what it means for infection prevention and control teams. From early lab detection to real-world frontline challenges, we discuss the key issues around this emerging pathogen — and what we need to do next. UK C. auris guidance can be found here: https://www.gov.uk/government/publications/candida-auris-laboratory-investigation-management-and-infection-prevention-and-control
Speakers: Dr Katy Pike: Senior Lecturer at the University of Bristol, Honorary Consultant in Paediatric Respiratory Medicine and BNSSG ICB asthma lead Dr Deborah Marriage: Consultant nurse in Allergy and Asthma and BNSSG ICB asthma lead Blurb: Hot of the press: NICE, BTS and SIGN all reached agreement for new, revolutionary asthma guidelines. In this episode Katy Pike and Deb Marriage demystify the guidelines, guiding us through the changes and impacts for the diagnosis and management of asthma in Primary Care. Episode resources: New NICE/BTS/SIGN Asthma guideline Primary Care Respiratory Society: How to calculate and interpret peak flow rate variability Bristol Children's Hospital: Child asthma plan Bristol Children's Hospital: Teenage MART asthma plan Bristol Children's Hospital: Teenage non-MART asthma plan Asthma and Lung UK: Inhaler technique
What is a Clinical Pharmacologist? Who better to tell us than Professor Lauren Walker, Professor of Clinical Pharmacology & Therapeutics and Honorary Consultant in General Internal Medicine at Liverpool University. Lauren is a leading researcher in multimorbidity and AI-driven healthcare and plays a key role in early-phase clinical trials. We chat about her role in ‘First in Human' trials - what are they, what are the risks and why are they so important? And how does this work reach across to her clinical role which focuses on multimorbidity and polypharmacy. We discuss the role that AI may play in predicting polypharmacy and the development of DynAIRx - an Artificial Intelligence being designed to support medicines optimisation on multimorbid patients. It's a Robotic version of Steve the Chemist!Our micro-discussion continues with the theme of clinical trials. How can we ensure they are representative of the populations they are supposed to be treating. Is it ever ethical to test new drugs on elderly and frail patients? ‘The current status of inclusion of older groups in evaluations of new medications: Gaps and implementation needs to fill them' https://pubmed.ncbi.nlm.nih.gov/38600697/As with all of our guests, Lauren shares with us her Memory Evoking Medicine, a career anthem and book that has influenced her career or life. Fans of pharmacology will not be disappointed. Check out Lauren's impressive full bio here, with further details of all of her research: https://www.liverpool.ac.uk/people/lauren-walkerThis week we also discuss Steve's impressive TV debut where he describes the role of a Clinical Pharmacist to none other than Professor Green on BBC Morning Live. This is a must watch for anyone who wants to understand this role and the impact of polypharmacy. A new career beckons… You can watch it here: https://www.rpharms.com/about-us/news/details/polypharmacy-featured-on-bbcs-morning-live. Our website is https://www.theauralapothecary.com/You can listen to the Aural Apothecary playlist here; https://open.spotify.com/playlist/3OsWj4w8sxsvuwR9zMXgn5?si=tiHXrQI7QsGtSQwPyz1KBg You can view the Aural Apothecary Library here; https://litalist.com/shelf/view-bookcase?publicId=KN6E3O To get in touch follow us on Bluesky and X @auralapothecary or email us at auralapothecarypod@gmail.com . Don't forget to rate us and comment wherever you have got this podcast from.
TopMedTalk is at The American Society of Anesthesiologists (ASA)'s annual general meeting; Anesthesiology 2024. Here we discuss key anesthesia updates, emphasizing patient safety and comfort. Does the evidence support allowing clear liquids up to surgery to reduce thirst without raising risks? Do new challenges around GLP-1 drugs, which delay stomach emptying, call for tailored pre-op guidance? Also, should we be rethinking gabapentinoids, which recent studies show may not effectively reduce opioid use as once believed? Presented by Desiree Chappell, Monty Mythen and Mike Grocott with their guests, Girish P. Joshi, Professor, Anesthesiology and Pain Management at UT Southwestern Medical Center and Ben Gibbison, Associate Professor of Cardiac Anaesthesia and Intensive Care at the University of Bristol, Honorary Consultant at University Hospitals Bristol and Weston NHS Foundation Trust.
In this episode, we explore the importance of patient involvement in shaping rare condition research initiatives. Our guests discuss why it's crucial to involve individuals with lived experiences, including patients and caregivers, in setting research agendas. In doing so, this approach ensures research can be more inclusive, efficient, and impactful, addressing the issues that matter most to those affected. Mel Dixon, Founder Cure DHDDS and member of Genomics England Participant Panel is joined by Jo Balfour, Founder of CamRARE and Dr Rona Smith, Senior Research Associate at the University of Cambridge and Honorary Consultant in Nephrology and Vasculitis. Find out more about the Cambridge Rare Disease Research Network, discussed in the episode, which aims to support the rare condition community in building an online network of partnerships and resources to facilitate new patient-centred research opportunities. "We're really turning research on its head, moving away from it being a researcher-led activity where they decide on the idea and the research concept and bring patients in at different points along that research journey and instead starting with the patient's idea in the first place. It can only be a better system for all because it improves efficiency, it improves potentially the long term outputs and, most importantly, outcomes for patients." You can download the transcript or read it below. Mel: Welcome to Behind the Genes. Rona: I think it really means that we measure what matters to patients and individuals that are affected. Often, it's really difficult to capture kind of the real impact of disease and there's a tendency for researchers to measure things that are easy to measure and are reproducible, which of course is important but what's most important is actually being able to truly capture the impact of an intervention on an individual's condition. So, I think that's another key aspect of having people with lived experience involved right from the start. Mel: My name is Mel Dixon and I'm a member of the Participant Panel at Genomics England and founder of Cure DHDDS, a charity set up to raise awareness, support families and help drive research into the ultra-rare DHDDS gene variant. On today's episode I'm joined by Jo Balfour, Managing Director of CamRARE, which is the Cambridge Rare Disease Network. This network unites patients, advocates, experts and leaders to address the challenges faced by people affected by rare conditions. I'm also joined by Rona Smith, Associate Professor at the University of Cambridge and honorary consultant in nephrology and vasculitis. Today we'll be discussing the role of patients in setting research agendas and how their involvement can lead to more impactful and patient-centred research. If you enjoy today's episode we'd love your support. Please like, share and rate us on wherever you listen to your podcasts. Before we begin the interview I'd like to share a little bit of my story. In November 2022, following whole genome sequencing, we received the news that two of our three children carried a neurodevelopmental and neurodegenerative DHDDS genetic variant. At the time of our children's diagnosis there was very little information on our gene, minimal research happening into it and no treatment pathway. Through our charity, Cure DHDDS, we have worked tirelessly to instigate research and create a collaborative scientific research community. I am a huge advocate for patient-led research and have witnessed first-hand the positive impact it can have on patient lives. Thanks to the work of the many scientists that we have had the honour of collaborating with, within two years of our children's diagnosis we have a disease-modifying therapy in our sight and an ASO (Antisense oligonucleotides) therapy in development. We are incredibly grateful for the opportunities genetic testing has given us but I also appreciate how overwhelming a genetic diagnosis can be and how challenging it can be for families to initiate research projects with little to no resources, and that's why initiatives such as CamRARE that we'll be discussing today are so important. On that note, let's get back to our podcast guests. I wonder before we dive into today's topic if you could both give a brief introduction, and, Rona, if you could also give the less scientifically-minded of us an explanation about what nephrology is. Rona: Thank you for inviting me today. So I'm Rona Smith, I work in Cambridge and I'm a nephrologist and that means somebody that looks after individuals who have diseases that affect their kidneys. My specialist interest is in something called vasculitis which is a rare autoimmune disease that affects all organs in the body but kidneys as well. Mel: Thank you. And Jo? Jo: Hi Mel. I'm Jo Balfour, the Managing Director and one of the founding members of Cambridge Rare Disease Network, or CamRARE for short. I think we're often described as the ‘Chief Everything Officers'. I manage the charity and all of our operations and our wonderful team. Mel: Lovely. Thank you very much. Rona, I wonder also if you could explain to our listeners what is a research agenda? Rona: So in brief a research agenda is really a strategy that outlines key questions or topics that a research community, and that might be investigators, clinicians, scientists, patients, industry, and they are the priorities that they want to explore and address over a period of time. So it's really a direction of travel and identification of areas of importance and where there are gaps in knowledge so that it then leads to the opportunity to form specific research questions that you can then go on and address. Mel: Why do you both think it's important to involve patients in setting these research agendas? Jo: Well I think critically one of the things that I've learnt over my time working, not just in the rare disease sector but also earlier in social care and education, is that we should as professionals never assume anything; you know, we have not lived in their shoes and we don't know what the daily life of people living with rare conditions is like. So gathering that day to day lived experience is really crucial. And I have a unique opportunity to see into that daily life with our local community of rare disease families who have a range of different rare conditions. I'm party to their conversations, to their daily trials and tribulations, the things that are difficult, the things that they find joy in but I still will always go back to them and ask their opinion. I see myself as a spokesperson for them as we're an umbrella organisation but I certainly never really know what it's like to live with their conditions. I think they bring with them diverse experiences which we really need and value in setting research priorities, they have unique knowledge of their own conditions. They ethically have a right to be involved from the start and to set that priority and agenda but, equally, it's valuable for us as researchers because if we can involve people early we have definitely more chance of good engagement and later success, better outcomes for everyone. Mel: Couldn't agree more. And, Rona, is there anything you'd like to add to that? Rona: I think it really means that we measure what matters to patients and individuals that are affected. Often it's really difficult to capture kind of the real impact of disease and there's a tendency for researchers to measure things that are easy to measure and are reproducible, which of course is important but what's most important is actually being able to truly capture the impact of an intervention on an individual's condition. So I think that's another key aspect of having people with lived experience involved right from the start. Jo: Another thing that's actually quite interesting that I'm going to mention here is that I think when you live day in, day out with a condition your perception of things like pain is different from your average person's so you become almost accepting of your daily norm, and I think that's really critical to understand as well. And it's only by getting to really know patients and understand. When we say, “What's your pain like on a scale of 1 to 10?” you know, something that I feel as pain because I get it rarely I probably am going to put it at a higher score than somebody who has that every day. So I think there's subtleties and nuances like that as well which are really critical to get across by conversation with patients. Mel: That makes absolute sense. And I see that from the patient perspective myself. I was out with my friends the other day and they said, “Oh my goodness, you're constantly taking your children to sports activities.” Because of their physical needs we're constantly, they go to Pilates, they go to swimming, they go to gym class – we try to keep them fit and healthy – and we, even though they're older, have to take them there and back and that's become our norm but when you're speaking to families whose children don't have those difficulties they have no idea how much time that actually takes up. And I had no idea how much like time it takes up compared to what other people are doing because that is our norm, that's what we've accepted as the norm. Patients and patient groups are incredibly driven and invested in their rare disease as well so they make really good rare disease research partners. And, moving on, what do you see as the challenges and barriers to patient involvement and how do we overcome these? Rona: I think probably the biggest barrier is time. So, the most important thing is investing time to build relationships, to really understand in-depth perspectives both from the patient's side but also the researcher's side. And, inevitably, we always want to do things faster and actually this is one really, really critical aspect is investing time. Funding is also a challenge. Often you have to do a lot of upstream work before you have got funding for a project and that takes time from individuals and that's another challenge. And I think the third thing for me is individuals that are patient partners in research, they're not just patients, they're people - they have lives, they have work, they have families, they have everything else that goes on in life - and so actually fitting this all in is really challenging. Mel: Jo, is there anything you'd like to add there? Jo: Yeah, I think just a word about diversity really and, you know, how do we uncover those hidden families and patients who currently don't really have a voice. I think we'd all acknowledge that there are key voices within the rare disease community who will share the views of their community and they've become well-oiled machines almost at being great advocates but, as I mentioned earlier, even though I'm perhaps one of those people, you know, I speak for a community, I would never assume anything. So, I still need to uncover the thoughts and the feelings and the emotions and the needs and the what matters from those people, and, as Rona mentioned, that takes time and it takes building relationships and trust with people. So, we have a wonderful community in the Eastern region of England which is made up of families affected by all different rare diseases, and undiagnosed. And some are babies and have been lucky enough to get a very early diagnosis and others are young adults but what we're finding through that is that experience is diverse and experience changes over time as families go through transition periods or they meet a roadblock and they're having to navigate things differently. So, it's about building those relationships. That takes times, it takes resources, it takes sometimes a reset in the way that we think things need to be done. So instead of asking questions all the time and putting surveys out and trying to get response that way it takes a bit of thinking about how do we listen better and how do we give those people who don't have a voice, who are non-verbal or perhaps have a learning disability, how do we ensure that we're capturing their views as well. And we did a really lovely project actually last year, it was something funded by the NHS called My Story, My Way, where we actually spent three months with our young adults working out what it was they wanted from our community next, how did they want us to follow them into adulthood. And we knew that there were a number of young people in that group who were non-verbal and had some learning differences and we knew that we couldn't just do it in the normal format, we couldn't just do a focus group and ask their opinion, so we actually did it through photography. So each of the familiess well, the young person themself was given a simple camera. They basically had thirty-six shots. You got thirty-six clicks to capture the things, the people, the places that you love and then to share them with us as a community. And then we all discuss, you know, how these things might be something we can build into our future plans for them. And it was such a wonderful activity. We gave them plenty of time, plenty of opportunities to ask questions. If the young person themself couldn't physically click the camera their sibling got to help them. And their sibling or their parent was given another camera in black and white so we had distinctive pictures, pictures that the kid themself had taken, pictures that the family had taken, but all together, you know, it gave this lovely kind of medley, this beautiful visual representations of what mattered to them. And I think it's about taking the time to be creative with people like that and really get to the bottom of “How do we find out what matters to you?” Mel: Although it takes time to think about those ideas. That could be translatable across the board really, couldn't it, throughout various conditions. I think that's fantastic. Rona, I wonder if you can tell us how has the work that's already been done through the patient-led research hub facilitated addressing research priorities. Rona: So just a tiny bit about the patient-led research hub. So, this has been now running for nearly ten years through Cambridge. It's a partnership between the Cambridge Biomedical Research Campus and we're based within the university and the Trust. And in essence it kind of was set up because of really a mismatch between what many patients wanted from research and what investigators' views were. And so really the premise is that we welcome patients to come to us with an idea, a problem, an unmet need in their disease area – and we do focus on rare disease – and we work with them to see “Well actually what do we already know about that?” and then if there is a gap in knowledge we then move to kind of trying to work and develop a question that we can then address. And that might be a question that's addressed through generating more information through surveys or it may actually be a question of an intervention that we can test. So, we've had lots of projects come through and we, just an example of a project was from a group of patients with a rare kidney condition called autosomal dominant polycystic kidney disease, and that is a condition where over time you accumulate cysts in your kidneys and the kidneys become large, they become very painful and eventually they can fail. And a question that the patient group had was about whether drinking more water could impact the rate of growth of these cysts, and there's a strong hypothesis behind that that drinking lots of water reduces down the level of a particular hormone. And we actually worked with the charity behind this group, the Polycystic Kidney Disease Charity, and designed a study to test a very high water intake to a normal water intake to see whether it was possible over a period of eight weeks for patients to actually stick to this. It's quite difficult to do. And they recorded how much water they'd drunk, they tested their own urine and actually it showed that this was feasible to do this kind of work. So, I think the patient-led research hub is kind of taking the research priorities that are important to patients but working in a patient-led way to come right through to a project. Mel: That sounds great. And if the patients are engaged from the start of the project and it's led by them they're obviously going to be much more driven to take part in the actual research and see the research through themselves. So, Jo, I'm very excited to hear about the launch of the Rare Disease Research Network. Can you please tell me what the research network is and what you hope to achieve with it? Jo: So the Rare Disease Research Network is first of all a bit of a mouthful so we're going to try and encourage people to call it the RDRN. It's a co-created project which really the patient-led research hub in Cambridge approached us about in 2022, I think, we started talking about this, approached CamRARE as a partner to apply for an NIHR partnership grant, and we were successful with that to really take the model that the patient-led research hub had already developed and found was successful, and perhaps too successful for its own good – they were receiving more applications and more ideas than they could manage – and to develop that into an online platform. So taking the same model, making it more accessible to a wider group of people, potentially worldwide, and providing the hand-holding that the patient-led research hub has always done, helping patients really consider their question, formulate that into a research idea, then do the literature search to find out “Is this question already answered, and if it is, great, can we provide that information to our community? If it's not, how do we then build a team? Who needs to be in my research team? How do we then get funding together to take this idea forward?” So, it's really taking the model, taking the good practice that already existed and creating an online platform to really attempt to replicate that as best we can. So the platform will launch on 23rd November (2024) at CamRARE's Rarefest which is a lovely in-person activity that's going on in Cambridge, and that platform will be open to anyone who has an interest in rare disease research. But I think, critically, what's different about this is that, you know, we've talked about setting research agendas and we've talked about patients contributing to that, contributing to setting the priorities, what's different here is that the patients decide on the questions; it's what matters to the patients coming from them and their community. And it's an opportunity for them to showcase those questions and those idea on a platform and almost to have a call to action, “Is there anyone else on this platform who has similar research interests to me?” The platform will matchmake them together through a series of choosing tags, choosing tags about particular disease areas - It's linked to the Orphanet database - choosing tags about the type of research that you're interested in. That matchmaking process will happen, which at the moment is a very serendipitous process but we hope to take it a little bit further on from that. It's still going to be a little bit of potluck who's on the platform at the time who's got similar interests as you but hopefully it will improve that serendipitous system. And it will allow them to access resources on the platform, which is the kind of hand-holding bit, and also, critically, some mentoring. So, there's a real sort of opportunity here for professionals – researchers, industry partners, healthcare professionals – who have particular skills in research to be able to say, “Well I can help. I might not be able to be part of your team at this point but if you need half an hour on a Zoom call with me to think about your research question I can offer to mentor you on that.” But, likewise, I think there's going to be lovely opportunities here for patient groups to support each other too because what we've always realised is that patient groups are at different points of their research journey. You know, we see some organisations that are really well-funded now who are in partnership with industry, you know, they have a group of pharma companies that are supporting the development of treatments and they've kind of reached that point where they're very highly skilled and very well experienced. And then there's others who are mum and dad who've just had a recent diagnosis for their child, they've gone searching on the internet, they can't find information, they don't have a patient organisation to rely on so they're going to make one themselves. This happens all the time in the rare disease field. There are 11,000 different rare conditions and there's not a group for all of them so mum and dad will often start something themselves and then in lots of cases want to do some research, they want to answer some of these questions. So, you know, they're really starting from a very different beginning stage here where they've going to need some help, and sometimes the best help comes from their peers, it comes from other patient groups. So that's in a nutshell what it's about; it's about providing opportunity for patient groups to showcase their great ideas, build partnerships and take research forward. Rona: The only thing just to add there is I think, although rare diseases are individually rare, collectively, as Jo said, they're quite common, there's 11,000 rare diseases, and often, although they all have distinct features, there are common threads through rare diseases in terms of maybe symptoms that patients experience or challenges that their rare disease brings. So, for example, you may have symptoms of pain or seizures that are common across many conditions, there may be educational needs that are threads going through. And groups could work together maybe to answer a question that's relevant to a number of conditions and so bringing people together for that. Or there may be another group that's already tried to answer that question in their condition and you can learn what worked, what didn't work. I think that's the other thing, is there will be common threads that come through, and I think that would be a real strength of the network to draw those people together. Jo: I think as well, Mel, if we take this back to what we said right at the outset about optimising success for patients by bringing them into the conversation early, I think this platform provides the perfect opportunity to do that. So we're moving away from, we're really turning research on its head, moving away from it being a researcher-led activity where they decide on the idea and the research concept and bring patients in at different points along that research journey and instead starting with the patient's idea in the first place. It can only be a better system for all because it improves efficiency, it improves potentially the long-term outputs and, most importantly, outcomes for patients. Mel: We were that family, that mum and dad setting up the charity a year and a half ago for the ultra-rare disease that our children had. I think, you know, the match-making opportunities that are here are fantastic because finding yourself in that position is incredibly isolating. And not only the matchmaking opportunities with the researchers but, as you were saying, Rona, as well with similar diseases; there's so much to learn from other diseases that may have, I don't know, a similar phenotype in the cells or similar symptoms. That's what we found from connecting with these other rare conditions. So, for us it's lysosomal storage diseases, we've now got the opportunity potentially to piggyback on drugs better used for their diseases for our own ultra rare condition, you know, where for us to run a full-on clinical trial by ourselves with a new drug, I mean, we just wouldn't have, there's no funding, there's not enough interest. So, I think the opportunities that lie in this network are really, really exciting. Jo, can you tell me a bit more about who can join the research network? Jo: So anyone with a rare disease research interest. That's everybody from individuals affected themselves, their family members, their caregivers, the patient organisations, that support them, and then, you know, all sorts of rare disease professional researchers. So, we're looking for PhD students who are looking for their first exciting project to undertake, have they taken a look at the Rare Disease Research Network to see if there's any ideas that might pique their interest. We're looking for established researchers, medical professionals who are undertaking clinical research but also I think, importantly, companies. You know, we hear more and more about concepts like drug repurposing for rare diseases where we're looking at the opportunities for taking drugs that already exist and have been proven safe to be redeployed to other rare diseases. It's quicker, it's more efficient, it's cheaper, so does it open up opportunities for companies that are using that technique to get involved. And also pharma companies. This platform is not all going to be about finding cures and treatments but it certainly will be a priority for some groups. So we really are welcoming everyone with an interest in rare disease research to get involved, be part of the network, collaborate, help where you can. Rona: And also, as we've said before, once you've got that level of engagement and the patients leading these initiatives we've found, certainly with our group, the patients are much more willing to, say, find the MRI scans for the scientists, to have a blood sample done, to have skin fibroblasts taken. If they know and they understand and they're driven and, as you said, the research idea has come from them as a patient group it certainly increases the chance of them being fully involved in the project from the start to the finish. And all these things are imperative to understanding rare conditions because without researchers having the opportunity to look at these various samples you're not going to stand much of a chance of finding a treatment. Jo: And we want the opportunity to upskill patients as well. I think there are many people out there with great ideas who haven't yet found the confidence to promote those ideas because they're not quite sure of what the research journey looks like or what it might entail or whether they've got the right skills. But I think by joining the platform and almost kind of watching how other people are managing these things and utilising the resources and the mentoring I do really hope that will build that confidence and those skills sets in people so that they can engage. Rona: Yeah, just to add to that, I don't think it's just upskilling patients and patient groups, I think it's upskilling everybody involved in rare disease research. This is quite a different way of approaching research, it's something that maybe academics may feel a little bit uncomfortable with, it's not how it's normally done, so I think there's a whole learning process. And the aim is that this RDR network will evolve and will develop and the direction it goes will be driven by the community that are engaging with it. So I think it's a really exciting time just as we're coming up to launch to see where this goes. Jo: Mel, you've been involved in this project, it would be really interesting actually to hear from you. I was just thinking, as part of the co-creation community we had 25 individuals from the rare disease community who built this platform from scratch with us; Rona and I might have set out all the vision for how we wanted the platform to be or what we thought might be a good idea but ultimately it was the community who decided and they literally have fact-checked and cross-referenced every word that's gone on the platform. What has that experience been like for you as a patient representative? Mel: I think it's been really welcome to see a network that is truly putting patients at the centre of everything. So, from the very beginning foundations you have the rare disease community involved which is exactly what you're trying to create through your network. So, I think it's been very welcome to be involved in the project and I also think that hopefully it will sort of be self-perpetuating that this will start to press a reset button on how we think about rare conditions and how it needs to be a more equitable field with patients. Because I think, as you've both alluded to, while some clinicians and researchers are very onboard with this, for others it's a new concept that they still need to potentially adjust to or get their head round because it is a different way of thinking. But in rare disease, well, in any condition really but particularly rare disease because there's so few experiences to draw on, I think that patients are vital to moving forward and to making that change so that diseases and conditions that have previously had no treatment, like, hopefully this way of thinking can expedite those treatments because, well, as a rare disease representative myself for our community that's one of our biggest drivers. We're dealing with a condition that's progressive that affects most of our community's children; that is what we want, we want treatment, we want something that can stabilise the conditions. You know, you can have researchers doing random projects that would make no difference to the final outcome of patients but if researchers know it's a priority of this particular group, hopefully that can channel in their focus and get the outcomes that the patients want in a more timely collaborative way. So, I am a huge advocate for what you're doing, I think it's an incredible initiative. Is there anything either of you would like to add to that? Rona: Rare disease disproportionately affects children and young people. So, 7 out of 10 rare diseases develop in childhood and at the moment the Rare Disease Research Network hasn't really got a forum for including children and young people, and really that's partly because, and Jo can speak much more eloquently to this with her experience. Actually, we didn't do that at the start because we feel that this is actually a discreet piece of work that really needs to be done in collaboration with children and young people to make sure that it's done well so that they can engage in the platform. So, Jo, I don't know if you want to talk about how we're hoping to take this forward. Jo: Yeah, so we're busy developing a project plan at the moment which we're hoping to get funding for to work over eighteen months with a team of young adults with rare conditions, probably from our Unique Feet community and keep it local because we already have a good relationship with them and they have our trust. But the idea would be to work with lots of other young people's forums. So there's already ones established in and around our area, such as Pedal, which works with really small children, and there's also groups that are set up for young people with cancer. So we've already had lots of great conversations with them about how we can work with them, how they can help us sense-check our project, and then in return we can help them better understand research and their ability to be involved in that. But ultimately by the end we want to run focus groups, we want to develop some peer mentors within our community, so young adults who've, you know, perhaps come out the other end of a period of transition into adulthood who can support other young people with rare diseases to also become researchers, to come up with their own ideas and their own questions, and to sense-check projects that come through the platform. So it's a really exciting opportunity to truly involve the people who are affected most by rare conditions but we know through our My Story, My Way project that this has to be done gently, carefully, given time and done really thoughtfully. So that's our next step and we hope to be able to share those learnings with people so that it can be done elsewhere. Mel: And do you see the network also working with children with learning differences? Jo: Absolutely. We'll invest a lot of time and energy in ensuring that materials are accessible, inclusive and suitable for the community that we're working with. Mel: So looking to the future, how do you think, Rona, can patient-led research help to shape the future landscape? Rona: So I think, Jo used the term earlier, kind of this is really turning research on its head, so it's really putting patients right at the centre of research, so it just makes sure that it's absolutely driven by what matters to them to get the outcomes that matter. And, again, it's just got all that benefit of efficiency and really answering those questions that matter. Mel: And, Jo, do you think this could lead to more collaborative partnership, for example, between industry and academia, potentially leading to quicker clinical advancement? Jo: I would absolutely like to think so. You know, as CamRARE we run a companies forum which is a roundtable meeting for pharma and biotech companies and other organisations like Genomics England who are involved in the rare disease therapeutic space and diagnostics, and I think one thing that I find really heart-warming about those meetings is that, you know, different companies are able to sit around a table as competitors but with a very open mind to addressing the barriers and the bottlenecks that prevent them from getting drugs to patients. Because of course it's not just the research journey that's a challenge, it's the regulatory side of things at the end of that journey; just because you've created a great drug it doesn't matter in the end if it doesn't get to the patient. So, you know, access is critical and involving patients at the earliest possible moment to ensure that that treatment gets through to the regulators and gets access to patients is the only way forward. We had a recent companies forum meeting where we were exploring health-related patient reported outcome measures, or PROMs, and we had a speaker from NICE who's the regulatory body, we had a speaker from Sheffield University who was talking as an academic about developing PROMs for industry and for patient groups and we had Emily Reuben, the CEO of Duchenne UK, and we had an amazing discussion about the importance of involving the patient community from the outset. And the academic explained that developing a PROM for Duchenne UK had taken them two years and it had taken them that length of time because they'd followed this careful thoughtful pathway of making sure that they didn't assume anything about what matters to patients. But that of course, as we said earlier, involves time, it involves financial commitment, it involves resources and the right attitude, but I do think that a platform like the Rare Disease Research Network can really try to harness all of those things by bringing the right people together – industry, academia and patients – to work together equitably. Mel: And with the network do you think you'll be getting the regulators in at that initial stage as well so that, like you said, the patients can gain access while we're dealing with their priorities, the regulators are informed at the very earliest stages so that we know the process that's being followed will ultimately lead to patients gaining access to the relevant therapies? Jo: Yes, I think this is really important, and there's actually, we've got a section on the new platform which really talks to each of the different stakeholders. ‘What's in this for me?' ‘Why is it important for you to be here and to join?' And one part of that is funders and that includes the regulatory bodies. And at the next companies forum meeting we're actually going to be bringing the Rare Disease Research Network Platform and its potential to the companies forum meeting and we'll have regulators involved in that. So, you know, we are constantly talking to people about why it's important for them all to be involved and all to see what matters. I think I'd like to advocate for an extra letter at the end of PPIEP - if we could squeeze a D in there at the end too. So over time that terminology has expanded to be Public Patient Involvement Engagement and Participation, which was added I think this year, but it would be lovely to have the D on the end and to include ‘Driven' because I think what's really important about this platform is that it's not just engagement and involvement, it's not just participation, it's initiated by and driven by patients. Mel: So I think we'll wrap here. Thank you to our guests, Jo Balfour and Dr Rona Smith, for joining me today as we discuss the role of patients in setting research agendas. If you'd like to hear more like this, please subscribe to Behind the Genes on your favourite podcast app. Thank you for listening. I've been your host, Mel Dixon, and this podcast was edited by Bill Griffin at Ventoux Digital and produced by Naimah Callachand.
Click here to subscribe for our podcast and video content on YouTube. This episode is an interview with Roger Barker, Professor of Clinical Neuroscience and Honorary Consultant in Neurology, at the University of Cambridge and Addenbrooke's Hospital. Dr. Barker is known for his groundbreaking work combining basic research on novel therapies for chronic neurodegenerative disorders, like Parkinson's, with clinical studies aimed at better defining these conditions. For more information about the Davis Phinney Foundation visit: https://dpf.org This content is made possible through the generous support of listeners like you. Click here to make a donation. Season 5 Episode 28
Guideline evolution is driven by ongoing research; recent studies like PeriOperative ISchemic Evaluation-3 Trial (POISE-3) and trials such as OPtimisation of Peri-operaTive CardIovascular Management to Improve Surgical outcomE II (OPTIMISE II) trial may influence recommendations on hemodynamic management and the use of tranexamic acid. Future guidelines are expected to integrate machine learning models for risk prediction, addressing complex patient phenotypes and interactions. Discontinuation vs. continuation of renin–angiotensin system inhibition before non-cardiac surgery: the SPACE trial has challenged existing practices regarding the discontinuation of ACE inhibitors or ARBs, highlighting the dynamic nature of medical guidelines and the continuous incorporation of new evidence to enhance patient care. Presented by Andy Cumpstey and Joff Lacey with Mark Edwards, Consultant in Anaesthesia and Perioperative Medicine, University Hospital Southampton Honorary Senior Clinical Lecturer, University of Southampton and John Whittle, Clinical Academic working in Perioperative Translational Medicine at UCL and Honorary Consultant in Perioperative Medicine, Anaesthesia and Critical Care at University College Hospitals London. -- More on POISE-3 here: https://clinicaltrials.gov/study/NCT03505723 More on OPTIMISE II here: https://optimiseii.org/ More on the SPACE trial here: https://doi.org/10.1093/eurheartj/ehad716
Dr Paul Turner, Reader/Clinician Scientist and Honorary Consultant at Imperial College London explains findings by a study his has conducted on food allergy prevalence in the UK. See omnystudio.com/listener for privacy information.
In this episode, we talk to Professor Clare Turnbull, Professor in Cancer Genetics at the Institute for Cancer Research and Honorary Consultant based at the Marsden. Title of paper: Breast cancer risk assessment for prescription of menopausal hormone therapy in women with a family history of breast cancer: an epidemiological modelling studyAvailable at: https://doi.org/10.3399/BJGP.2023.0327Prospective longitudinal studies (such as the Collaborative Group on Hormonal Factors in Breast Cancer [CGHFBC]) have enabled the estimation of relative risks of breast cancer associated with different durations of exposure to and formulations of menopausal hormonal therapy (MHT). Risk models such as BOADICEA enable prediction of age-related breast cancer risk according to the extent and pattern of breast cancer family history. This study undertook integration of these two data sources (namely the CGHFBC datasets and the BOADICEA model) in order to model annual and 5-year risks for breast cancer incidence for the age window 50–80 years for hypothetical unaffected female consultands with different patterns of MHT exposure and different patterns of breast cancer family history, also generating predictions for breast cancer-specific death. This study modelled combined and oestrogen-only MHT but lacked data for analyses of newer types of MHT such as micronised progesterone or non-oral preparations.
Euroanaesthesia is organised by The European Society of Intensive Care Medicine (ESICM). This year, TopMedTalk was there in Munich, Germany, bringing you exclusive coverage. What are the effects of up to 72 hours of perioperative ketamine on the risk of development of chronic post-surgical pain? How can we improve pain management and perioperative opioid use after surgery? More about the ROCKet Trial here: https://medicine.unimelb.edu.au/research-groups/critical-care-research/critcare/appmu/the-rocket-study More about PANDOS here: https://esaic.org/research/research-groups/pandos/ Presented by Desiree Chappell and Kate Leslie with their guests Patrice Forget, Professor, Clinical Chair in Anaesthesia at the University of Aberdeen (UK), and Honorary Consultant at the NHS Grampian, Chair of the PANDOS (Pain AND Opioids after Surgery) ESAIC Research Group and Philip Peyton, Head of research in the department of anaesthesia at Austin Health and Professorial Fellow in the Anaesthesia, Perioperative and Pain Medicine Unit, Melbourne Medical School, University of Melbourne, Australia.
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Alexander Ford, MD Irritable bowel syndrome (IBS) is diagnosed using the ROME 4 criteria, and fortunately, most patients who meet the criteria for IBS clinically are unlikely to have another underlying explanation for their symptoms. However, a common misconception is that IBS is a diagnosis of exclusion, so to learn more about this and other controversies surrounding IBS, join Dr. Peter Buch as he speaks with Dr. Alexander Ford, Professor of Gastroenterology and Honorary Consultant of Gastroenterology at Leeds Institute of Medical Research at St. James University of Leeds.
Frank Waldron-Lynch is a globally recognised Physician-Scientist with over two decades of experience in leading research and clinical development in autoimmunity, transplant immunology, and rare diseases across academia, biotech, and pharmaceutical sectors. Frank is a distinguished Consultant Clinician with multi-layer expertise in Immunology, Translational Medicine, Internal Medicine, Endocrinology, and Metabolism. A strategic leader and independent thinker with a proven track record in hiring talent, forming, developing, and mentoring high performing teams that consistently deliver transformative therapies for patients. Most recently, Frank held the position of VP, Cell Therapy, and Immunology Research at Vertex, in Boston, USA. Prior to this Frank held the position of Translational Medicine Expert and Global Inflammasome Lead at Novartis Institutes for Biomedical Research, Basal, Switzerland, and spent several years on faculty at University of Cambridge, where he was a Senior Clinical Trials Fellow in the Division of Experimental Medicine and Therapeutics, as well as being an Honorary Consultant in Endocrinology and Internal Medicine at Addenbrookes Hospital, Cambridge, UK. Dr. Waldron-Lynch, BSc, MA, MB, BChir (Cantab), PhD, FRCP (Lond), FRCPI, trained in academic and clinical medicine at Yale University, University of Cambridge, University College Cork, and University of Galway. He has published numerous scholarly articles in his research areas of interest and holds fellowships from the Royal College of Physicians of the United Kingdom and the Royal College of Physicians of Ireland. Frank (OC 89) is married to Maeve and has two sons who both currently attend Clongowes Wood College. Both his father Derrick (OC 54) and brother Tom (OC 87) also attended Clongowes. In his spare time, he enjoys snowboarding, sailing, and gardening. Frank left Clongowes in 1989 --- Send in a voice message: https://podcasters.spotify.com/pod/show/portraitsofclongowes/message
In this International Women's Day special, Jane Dacre chats with Dame Lesley Regan, Professor of Obstetrics and Gynaecology at Imperial College's St Mary's Hospital Campus, and Honorary Consultant in Gynaecology at the Imperial College NHS Trust. Lesley combines her clinical and research work on recurrent miscarriage and uterine fibroids with a passion for communicating to the wider public, writing two successful books on miscarriage and pregnancy for the general reader and presenting a series of eight BBC 'Horizon' documentaries.For transcript: https://www.ucl.ac.uk/medical-sciences/medical-women-talking-podcast Date of episode recording: 2024-02-29T00:00:00Z Duration: 00:34:21 Language of episode: English Presenter: Professor Dame Jane Dacre Guests: Professor Dame Lesley Regan Producer: Matt Aucott
In this episode, we talk to Dr Shamil Haroon, Associate Clinical Professor and Honorary Consultant in Public Health Medicine at the University of Birmingham, and Dr Prasad Nagakumar, a Paediatric Respiratory Consultant. Title of paper: Post-hospitalisation asthma management in primary care: a retrospective cohort studyAvailable at: https://doi.org/10.3399/BJGP.2023.0214Asthma is a common cause of hospital admissions and clinical guidelines recommend that hospitalised patients are followed up in primary care. Little research has been done on 3 evaluating post-hospitalisation asthma management in primary care. We found that 40% of hospitalised patients did not receive asthma management in primary care following hospital discharge, particularly among patients from black ethnic minority groups. Primary and secondary care services should develop systems for ensuring the timely follow-up of asthma patients after hospital discharge and address the observed health inequities.
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Stefano Pluchino, MD, PhD An international collaborative phase 1 study has shown that the injection of a specific form of stem cells into the brains of patients with progressive multiple sclerosis is safe and effective in preventing further brain damage. However, a different type of clinical trial is needed to address whether an advanced cell therapy made of brain-specific stem cells is indeed leading to amelioration of disease features. Take a deeper look into the findings from this study as Dr. Charles Turck speaks with the author of the study, Dr. Stefano Pluchino, Professor of Regenerative Neuroimmunology and Honorary Consultant in Neurology in the Department of Clinical Neurosciences at Cambridge University.
In the captivating Episode 73, Sunny and Mayank sit down for a thought-provoking conversation with Matthieu Komorowski, a Senior Lecturer at Imperial College in London and an Honorary Consultant in Intensive Care and Anaesthesia at the NHS. From from the East of France originally, Matthieu opens up about his upbringing as the middle child in a middle-class family—a crucial aspect that has significantly shaped his emotional maturity.Reflecting on his childhood, Matthieu shares how growing up in an emotionally immature family has influenced his present self. He candidly discusses how this background fueled his inner drive to "be someone" in order to garner recognition and value from his family and friends. This deeply rooted desire for validation led him on an ambitious path, one that saw him aspiring to become an astronaut. Matthieu recounts his experience of making it to the final 94 candidates for an astronaut position, only to face heartbreaking rejection due to a low heart rate.Against the backdrop of Matthieu's personal journey, Mayank and Sunny navigate a discussion on the dangers of the happiness trap. They explore the complexities of the pursuit of happiness, the analysis paralysis that can accompany the quest for finding meaning and answers, and the toxic behaviors that can emerge when one is driven by an insatiable desire for more.Join Mayank and Sunny in this introspective episode as they delve into the layers of Matthieu Komorowski's life, unpacking the intricacies of ambition, emotional resilience, and the pursuit of fulfillment in the face of setbacks.______________LinkedIn: https://www.linkedin.com/in/matthieukomorowski/______________There are some sensitive topics we touch on regarding mental health so if there are any triggers for you please know there is support and there will be plenty of links in access below.LifeLine (Australia) - Ph: 13 11 14 https://www.lifeline.org.au/Banksia Project - https://thebanksiaproject.org.au/Mr. Perfect - https://mrperfect.org.au/NHS (UK) - Urgent mental health support https://www.nhs.uk/service-search/mental-health/find-an-urgent-mental-health-helpline______________As always, Bottled Up is a passion project to help provide a voice to those many men who are going through the peaks and troughs of life. We are not trained professionals and if you're worried about someone close to you and their mental wellbeing, it's important to get professional advice.Start a conversation with them and let them know that they're not alone and that there are many support resources out there - including friends, family, school chaplains and plenty more!If you're feeling distressed or overwhelmed, Beyond Blue has a number of trained mental health professionals available 24/7 on 1800 512 348.For immediate support, call Lifeline on 13 11 44 and in an emergency, always dial 000.______________Music: https://www.purple-planet.com
The publication of this podcast was funded by QIAGEN. Tune in to our latest podcast for valuable insights on non-small cell lung cancer (NSCLC). Esteemed contributors to this discussion include Terri Conneran, a Patient Advocate and founder of KRAS Kickers, and Colin Lindsay, a Clinical Senior Lecturer and Honorary Consultant in Thoracic Medical Oncology at The Christie in Manchester, UK. Both experts underscore the pivotal importance of biomarkers, diagnostic technologies, and collaborative efforts in enhancing survivorship. During this episode, you'll hear about the need for early biomarker testing in NSCLC, along with a forward-looking exploration of the field's future. Lindsay offers an overview of the current treatment landscape for NSCLC, shedding light on issues like late diagnosis and targeted therapies, as well as outlining next-generation sequencing and liquid biopsy as tools to enhance NSCLC testing. Patient experiences are explored, with Conneran sharing her personal journey with diagnosis and treatment. Speaker Bios: Terri Conneran – Patient Advocate and Founder of KRAS Kickers, Charlotte, North Carolina. United States. Colin Lindsay - Clinical Senior Lecturer and Honorary Consultant in Thoracic Medical Oncology at The Christie, Manchester
In this episode of Heads Up podcast, we unravel the connection between migraine and facial pain, where migraine can often manifest as debilitating facial discomfort. Join our host, Dr Katy Munro, a leading Headache Specialist, as she engages in a captivating conversation with the renowned Professor Tara Renton, an expert in oral surgery. Professor Renton, based at Kings College London and serving as an Honorary Consultant for both Kings College Hospital Foundation Trust and Guys and St Thomas Foundation Trust, shares her extensive knowledge on the nuanced world of migraine-related facial pain. This episode explores the intricacies of facial pain that can be attributed to migraine, sinusitis, and dental issues, providing essential insights into making the right diagnosis and knowing when it's time to seek dental care. Facial pain, often intertwined with migraine, can be misleading and complex. Sinusitis may present similar symptoms, further complicating the diagnostic process. By the end of this episode, you'll gain a comprehensive understanding of how migraine can manifest as facial pain, the potential overlap with sinusitis, and the critical role dentists play in managing these conditions. If you or someone you know grapples with migraine, facial pain, or sinusitis, this discussion is a must-listen. If you have any questions/comments or any topics you would like us to cover in our future episodes email: info@nationalmigrainecentre.org.uk. Important Links: http://trigeminalnerve.org.uk/ http://orofacialpain.org.uk/ WE ARE A CHARITY Please help us keep going in the following ways: Please donate to help us continue to release new episodes: https://www.justgiving.com/campaign/headsup
This piece is a guide to the importance behind drinking, eating and mobilising as part of an enhanced recovery after surgery programme (ERAS). It comprises clips from previous conversations, linked to below, along with a as yet to be released piece on the topic featuring Vicki Morton, Director of Clinical and Quality Outcomes at Providence Anesthesiology Associates in Charlotte, NC. Henrik Kehlet, gastrointestinal surgeon and former professor of surgery, Copenhagen University, and now professor of perioperative therapy and Head of Section of Surgical Pathophysiology, Rigshospitalet, Copenhagen University, spoke to us in more detail here: https://topmedtalk.libsyn.com/asa-henrik-kehlet-recovery-is-all-about-inflammation We speak with Ramani Moonesinghe, OBE, Professor of Perioperative Medicine at University College London and Honorary Consultant in Anaesthesia and Perioperative Medicine at University College London Hospital here: https://topmedtalk.libsyn.com/perioperative-quality-improvement-and-the-dreaming-question-ebpom-2023 We mention this paper “Is the pursuit of DREAMing (drinking, eating and mobilising) the ultimate goal of anaesthesia?” here: https://pubmed.ncbi.nlm.nih.gov/27079158/
In the second episode of the series Professor Lennox is joined by Professors Marian Knight and Fiona Alderdice to examine how mental illnesses impact women and families in the postnatal period, and the power of speaking out. Professor Marian Knight is the Director of Oxford's National Perinatal Epidemiology Unit (NPEU) and Honorary Consultant in Public Health with Public Health England. Professor Fiona Alderdice is Senior Social Scientist at Oxford's National Perinatal Epidemiology Unit (NPEU) and Honorary Chair in Perinatal Health and Wellbeing at Queen's University Belfast. Here, they explore how shame, guilt and stigma can lead to a deterioration in mental health for women after giving birth, and the need for more resource and research in this area. Content warning: Please be aware that this episode refers to depression, psychosis, PTSD and topics such as maternal suicide.
“It's kind of easy to say it; ‘drinking, eating, mobilizing' and yet actually what does it mean? Drinking, how much? Eating, what? And mobilizing, in what way? And so we refined the definitions so that everyone was measuring the same thing…” The Perioperative Quality Improvement Programme (PQIP): https://www.rcoa.ac.uk/research/research-projects/perioperative-quality-improvement-programme-pqip Presented by Desiree Chappell and Monty Mythen with their guest Ramani Moonesinghe, OBE, Professor of Perioperative Medicine at University College London and Honorary Consultant in Anaesthesia and Perioperative Medicine at University College London Hospital.
This episode features Mr. Maxim Horwitz. Maxim Horwitz is a Consultant Orthopaedic Hand and Wrist Surgeon in the Hand Unit at Chelsea and Westminster Hospital where he leads the paediatric hand surgery service. He is also an Honorary Consultant for the Major Trauma Unit at St Mary's Hospital and the Royal National Orthopaedic Hospital (RNOH) Stanmore. In this episode, Jane & Max give us an insight into Artificial Intelligence(AI) and its potential implications for Hand Surgery. Papers discussed - Insights and trends review: the role of three-dimensional technology in upper extremity surgery Evaluation of a convolutional neural network to identify scaphoid fractures on radiographs
Welcome to the Dr Coffee Podcast, brought to you by IndemniMed! In this week's coffee with consultants feature, I interview Dr Nick Brits, representing Urology. Dr Brits is originally from KwaZulu Natal, and completed his undergraduate degree at UCT in 2011. After internship in Pietermaritzburg he moved to Johannesburg and worked as a Medical Officer at Charlotte Maxeke and Chris Hani Baragwanath Academic Hospitals. He subsequently specialised in Urology at Wits and now works in private practice. Dr Brits is an Honorary Consultant at the University of Witwatersrand and is actively involved in undergraduate and post-graduate teaching and training in the field of Urology. When he's not practising his craft, Dr Brits enjoys spending time outdoors hiking, fishing, playing sport and spending time with his family and children. Thank you to our sponsors on today's episode: IndemniMed - https://www.indemnimed.co.za/ V Professional Services - https://vprofservices.com/ Seventh Star Tuition - https://seventhstar.co.za/
Topic discuss: “Diabetes" and "Child Labour" Presenter: Talib Man Plastic Pollution: Join Imran Akram for Monday's show from 4-6pm where we will be discussing: Diabetes It is commonly assumed that consuming too much sugar is the only cause of diabetes. However, this is not the case. Main causes of diabetes include insulin resistance, being overweight, hormonal disease and can also be passed down if already in family history. Join us as we dig deeper in its causes, the stigma attached to it and look at the ways in which diabetes can be managed if given right attention. Child Labour: Child labour continues to be a grave and persistent issue, violating the rights and well-being of millions of children. June 12th serves as a reminder of the global commitment to eradicate child labour and promote the well-being of children. We will be examining the global scope of Child labour and exploring country specific statistics, we hope to give insights into the extent of the problem and its impact on different regions. Join us for a thoughtful conversation on Child labour and how we can combat this dire situation. Guests: Dr Victoria Salem (Fellow in the Department of Bioengineering and an Honorary Consultant in Diabetes, Endocrinology and General Internal Medicine) Dr Shivani Misra (Consultant in diabetes and metabolic medicine at Welbeck Health, specialising in genetic diabetes, early onset type-2 diabetes and unusual type-1 and type-2 diabetes) Andrew Wallis (CEO of Unseen UK, chaired the landmark Centre for Social Justice report “It Happens Here”, widely acknowledged as the catalyst for the UK Modern Slavery Act of 2015, advising on its development) Ines Kaempfer is the CEO of The Centre for Child Rights Business (formerly CCR CSR) Producers: Ayesha Naseem, Tayyaba Nasir and Peter Man
This episode's guest is Dr Taher Mahmud, Co-Founder and Director of London Osteoporosis Clinic. Dr Mahmud trained at King's College Hospital, St Thomas' Hospital, and Guy's Hospital, and has extensive experience as an Honorary Consultant at the Royal National Hospital for Rheumatic Diseases in Bath and as Lead for Osteoporosis and Consultant Rheumatologist at Tunbridge Wells Hospital NHS Trust. He is committed to improving patient outcomes and eradicating osteoporosis-related suffering through his interests in holistic osteoporosis treatments, bone health advocacy, and patient feedback. Dr. Mahmud's MD and MSc research focused on drug side effects and he leads LOC with compassion and innovation. Dr Irene and Dr Mahmud discuss his choice of work in Rheumatology and Osteoporosis, the importance of bone health, treatments and lifestyle changes and early diagnosis. KEY TAKEAWAYS Dr Mahmud hopes to get people to get Osteoporosis diagnosed early so effective treatments to reverse the condition can be applied. Bone health is important for all generations to consider not just the elderly. You should eat healthily, avoid smoking and drinking, maintain a healthy weight and get regular exercise to keep your bone health from degrading in the long term. Dr Mahmud concentrates on transformational care which includes not just drugs but lifestyle changes. BEST MOMENTS‘We are really hoping that people can take an interest in their bone health at an earlier age so it doesn't result in any issues so we set up a foundation called Global Osteoporosis Foundation.'-Dr Mahmud‘If you had Rheumatoid Arthritis as a diagnosis some years ago it was tantamount to having severe coronary artery disease or a severe malignancy. Now..make the diagnosis very early we have very effective treatments.'-Dr Mahmud ‘If we can come from a place of service and abundance it helps us be our purpose and if people are helped then fantastic.'-Dr Mahmud‘Our main thing is not to incur an injury. If you have an injury it causes a whole bunch of other disruption and impacts your energy and your thinking and so on. Exercise definitely. Careful exercise.'-Dr Mahmud GUEST RESOURCEShttps://www.londonosteoporosisclinic.comGlobal Osteoporosis Foundation (Sticks and Stones) VALUABLE RESOURCESJoin Patreon : http://www.patreon.com/drirenechingInstagram: irene.ching.777Tiktok: @ireneching777Youtube channel: Dr Irene ChingTwitter: @ireneching7777Clubhouse: @ireneching1 https://www.facebook.com/irene.ching.735LinkedIn : https://www.linkedin.com/in/irene-ching-742623219 ABOUT THE HOSTDr Irene Ching is a medical practitioner who specialises in Family Medicine, Wealth and Life Coach, Property/ Business Investor, Speaker, and Podcaster : Be Happy, Healthy and Wealthy. Dr Ching speaks on health, wellness and wealth in talks, workshops and events. She has her own coaching programme on money mindset - Quantum Wealth Creation Accelerator (online course with weekly coaching). She approaches health and well-being in a holistic way and encourages people to look at all the areas of their lives. In her coaching sessions, she works with emotional freedom techniques, energy works, NLP, Intuition/ Superconscious mind, Inner child healing, Timeline therapy, Self love works, behavioural change, goal settings and money attraction healing. Her motto: Reset Your Mind, Reset Your life.The podcast Be Happy Healthy and Wealthy is aimed at people who want to be high achievers who perform at their peak performance in all aspects of life. It is about how we could be happy regardless of our circumstances, and to understand the secrets to real health and wealth; especially how to live a prosperous long life. She has been interviewing successful entrepreneurs, keynote speakers, influencers and millionaires on this important subject. So stay tuned to get the deep dive on how to be happy, healthy and wealthy- the million dollar questions!
“Gonadotropin therapy in male infants and adolescents with hypogonadotropic hypogonadism – what is the evidence and what should be best practice?” The Anne Klibanski Visiting Lecture Series was created to support and advance the careers of women. These lectures offer the opportunity for women faculty from outside institutions that have hosted Anne Klibanski Scholars to present on their expertise, either alone or in tandem with an Anne Klibanski Scholar. Presenter: Sasha Howard, PhD, Senior Lecturer and Honorary Consultant in Paediatric Endocrinology, Queen Mary, University of London Learning Objectives: Upon completion of this activity, participants will be able to: To understand the role of gonadotropins in male reproductive development To understand the potential for diagnosis and treatment of male hypogonadotropic hypogonadism in infancy (mini-puberty) To discuss the potential for induction or completion of adolescent puberty with gonadotropins, therapeutic options, and outcomes Click here to watch webinar.
Topic discuss “Diabetes and Maths" Presenter: Sheikh Sharjeel Tariq Bajwa Diabetes: Diabetes cases in the UK have reached an all-time high - 4.3 million people in the UK are currently living with a diagnosis of diabetes. Why is this figure increasing at such an alarming rate? Join us as we discuss the severity and health risks of diabetes, the various factors that can cause diabetes, and what you can be doing to prevent it. Maths: The UK Prime Minister Rishi Sunak has once again expressed his passion to promote maths in the education sector, by launching his plan to make it compulsory to study this subject until the age of 18. Critics have pointed to the issues this policy may pose, yet proponents have emphasised on how important numeracy skills are. Is maths really the solution for a better workforce? Guest: Tooba Rehman- Pharmacologist Sarah Finer- Clinical Reader and Honorary Consultant in Diabetes at the Wolfson Institute of Population Health. Deputy Lead for Genes & Health Partha Kar- National Specialty Advisor for the NHS Diabetes Programme for NHS England and Consultant in Diabetes and Endocrinology at Portsmouth Hospitals NHS Trust. Bridget Benelam- Nutrition Communications Manager, British Nutrition Foundation. Tony Astwood- Founder & Chair of the The Dyscalculia Centre Karima Esmail- Leading expert in the area of developmental dyscalculia Mr. Steve Chinn- an internationally regarded expert in the field of maths learning difficulties Sam Sims- Chief Executive of the independent charity National Numeracy Producers: Rabeeta Khan Hania Mubarik Fezia Haq
Welcome to season 1 of Conversations in Fetal Medicine, a podcast about the people who work in this field. This episode is an interview with Professor Christoph Lees. We talked about his path into fetal medicine, its challenges and joys, some of the research he's been involved with including the TRUFFLE study and High Intensity Focussed Ultrasound (HIFU), training, and his tips for people working in fetal medicine. See below for a more detailed biography. We have not included any patient identifiable information, and this podcast is intended for professional education rather than patient information. Please get in touch with feedback or suggestions for future guests or topics: conversationsinfetalmed@gmail.com. Music by Crowander ('Acoustic romance') used under creative commons licence. Podcast created, hosted and edited by Dr Jane Currie. Christoph is Professor of Obstetrics as Imperial College London; Honorary Consultant in Obstetrics and Head of Specialty for Fetal Medicine at the Centre for Fetal Care, Queen Charlotte's and Chelsea Hospital, Imperial College Healthcare NHS Trust; Clinical Director for Fetal Medicine for North West London and Visiting Professor KU Leuven (Belgium). Christoph qualified from Guy's Hospital, London in 1990. Following subspecialty accreditation in fetal-maternal medicine at King's College Hospital, London he established the fetal medicine unit at Addenbrooke's Hospital, Cambridge in 2001 and inaugurated the RCOG MFM subspecialty programme in 2006.His research interest is on fetal assessment and in particular the use of Doppler ultrasound to assess the health of the baby, scanning in labour, and non-invasive fetal surgery. He is the Chief Investigator of The Trial of Umbilical and Fetal Flow in Europe (TRUFFLE), a Collaboration of 51 Centres across Europe; co-founder of the International Working Group of Maternal Haemodynamics and Intrapartum ultrasound ISLANDs group. He is a Board member of the International Society of Ultrasound in Obstetrics and Gynaecology (ISUOG) 2015-2023, is chairman of the ISUOG Doppler and vascular imaging group and member then chair of the ISUOG Safety Committee (2018-2022).Professor Lees was awarded £2.2m grant from the Medical Research Council for first in human studies of high-intensity focused ultrasound in 2017, a £2.5m grant from the NIHR in 2019 to undertake the TRUFFLE 2 RCT and a £2.1M grant from the NIHR for a study on ultrasound of breech pregnancy at 36 weeks in 2023. In 2020 Professor Lees was awarded £253k by the MRC for the PANCOVID project, a Global registry of women affected by COVID-19 during pregnancy. He has published widely in scientific journals and has authored textbooks on fetal growth restriction, maternal haemodynamics and the widely read Dewhurst's Textbook of Obstetrics & Gynaecology.He has a strong interest in healthcare funding, medical regulatory issues and mentorship. With Professor Steve Smith, he set up the campaign group Doctors for Reform (2003-2011) comprising 1000 senior doctors that argued for a European type social health insurance system to supplement the NHS tax funded model. He has written papers for Civitas and Reform on the feasibility of this approach. He has written widely on GMC reform, was a consultant staff council mentor at Addenbrooke's (2010-2013), Chair of the Addenbrooke's Local Negotiating Committee and is a co-founder of the RCOG Supporting our Doctors group (2017).
In today's episode of Clinical Conversations Dr Hussun-Ara Shah interviews Dr Phil Crosbie about the Lung Health Check Pilot, the new national lung health checks and supporting patients with smoking cessation. Dr Crosbie is a Senior Lecturer and Honorary Consultant in Respiratory Medicine at the University of Manchester. His main clinical and research interest is lung cancer with a specific focus on early detection and screening. Phil is research lead for the Manchester Lung Health Check Service and co-chief investigator of the Yorkshire Cancer Research funded Yorkshire Lung Screening Trial. He is also member of the national Targeted Lung Health Check Expert Advisory Group and Early Detection lead for Cancer Research UK's Lung Cancer Centre of Excellence. -- Follow us -- https://www.instagram.com/rcpedintrainees https://twitter.com/RCPEdinTrainees -- Upcoming RCPE Events -- https://events.rcpe.ac.uk/ Feedback: cme@rcpe.ac.uk
Wednesday, 23 March 2022, 12:30am – 1:30pm 'Making Breath Visible: A Medical Humanities Approach' a seminar by Professor Jane MacNaughton (Durham) as part of the Medical and Health Humanities Lunchtime Seminar Series in association with Trinity Long Room Hub. The Trinity College Dublin Medical and Health Humanities Initiative brings together researchers from a wide range of disciplines including history, philosophy, sociology, drama, health sciences, religion, cultural studies, arts, literature and languages. Medical and health humanities seeks to provide insights into the cultural and social contexts within which diverse but interrelated concerns such as the human condition, the individual experience of illness and suffering, and the way medicine is (or was) practiced, might be understood. ‘What can medical humanities do to make breathlessness more visible and why is that important? As we (hopefully) start to emerge from two years of a pandemic that has literally stollen life and breath from millions around the world, I want to reflect upon a project that came to an end just as the pandemic started. That project, the Life of Breath, exemplifies a critical medical humanities approach in that it was interdisciplinary, concerned with lived experience, but also crucially, driven by a desire to make a difference for those most affected by this devastating symptom. I will reflect upon the invisibility of breathlessness in relation to embodied experience, but also in the social and political spheres, and explain how the medical humanities might help to open out the understanding and knowledge of that experience, and start to find ways of improving the lives of breathless people.' Bio Jane Macnaughton is Professor of Medical Humanities at Durham University in the UK and Deputy Vice Provost for Research. Until 2021 she was Director of the University's Institute for Medical Humanities (IMH). Jane has been centrally involved in the development of medical humanities in the UK since 1998. She was part of the working group that set up the Association for Medical Humanities in 2001, and she established the Northern Network for Medical Humanities Research in 2013. Her own work focusses on the idea of the embodied symptom and she has just completed a five year project exploring the lived experience of breathlessness. Jane was a member of the Wellcome Trust Expert Review Group for established career awards in medical humanities from 2010-2020. Jane is a qualified doctor and until recently did sessional work as an Honorary Consultant in Obstetrics and Gynaecology at the University Hospital of North Durham. The Trinity College Dublin Medical and Health Humanities initiative seeks to cultivate a richer understanding of the interactions and synergies between practices and discourses of wellness, health or medicine and the arts, humanities or culture through interdisciplinary research and education.
"Now we've declared it possible, is it the right thing to do?" This timely discussion considers the wisdom of day case total knee replacement: What do the data say? Can we do this without the use of opioids? What is reasonable to consider as part of an enhanced recovery after surgery program? How do patients make an informed decision when this kind of surgery is in their possible future? The first TopMedTalk piece mentioned in the discussion is here: TopMedTalk | Henrik Kehlet and Nick Scott: https://www.topmedtalk.com/topmedtalk-henrik-kehlet-and-nick-scott-2/ And the second is here: https://www.topmedtalk.com/cryoneurolysis-and-pain-management-topmedtalk-2/ Chaired by Sol Aronson, Emeritus Professor, Duke University & Desiree Chappell, VP Clinical Quality Northstar Anaesthesia with David Howard, Honorary Consultant, Ear Nose and Throat / Head and Neck Surgeon, Imperial and UCLH NHS Trust Hospitals, Brian O'Donnell, consultant anaesthesiologist, Cork University Hospital, Vinod Dasa, VP for Academic Affairs, Dept of Orthopedics, LSU.
The pandemic has caused many people to die alone in hospital intensive care units - whilst others have died at home without the support and pain relief they needed. The Lancet Commission on the Value of Death is calling for a radical change in how we approach death. Co-author Dr Libby Sallnow explains what makes a good death, and palliative care consultant Dr M R Rajagopal shares how communities have transformed palliative care in Kerala, India. Mixed messaging around Covid vaccines for pregnant women have resulted in a low uptake, leaving mothers and babies at risk of infection and serious complications. Dr Sarah Stock, an Honorary Consultant and Subspecialist in Maternal and Fetal Medicine at the University of Edinburgh, reassures us that vaccines are safe in pregnancy. Following the Spotify misinformation row, Marnie Chesterton asks how should streaming platforms respond to false claims about Covid-19? Professor Matt Fox from Boston University says they have a responsibility to tackle misinformation but warns that censorship may do more harm than good. Also, how a new scan is revealing hidden lung damage in long Covid, and should our chocolate treats come with picture warnings of clogged arteries? Presenter: Marnie Chesterton Producer: Paula McGrath and Samara Linton (Picture: A senior woman being comforted by a doctor in a hospice. Photo credit: Pornpak Khunatorn/Getty Images.)
“I hope it will happen in our lifetime, that we will start to learn how to use the totality of information that's available on tumours. And I don't just mean genomics, I mean any of it - including all the bits around the tumour, the microenvironment, the immune system. In the last 10 years alone, cancer research has grown phenomenally. It's been extraordinary to be involved in all of it. It's a very real privilege to be to be in this space.” In this week's episode of The G Word, Chris Wigley is joined by Serena Nik-Zainal, a consultant in clinical genetics, a Cancer Research UK Advanced Clinical Scientist at the University of Cambridge and an Honorary Consultant in Clinical Genetics at Addenbrooke's Hospital in Cambridge. She was the first woman to win the Josef Steiner Cancer Research Award in 2019. Serena discusses sharing data, personalised treatment for cancer patients and the impact of the 100,000 Genomes Project. She also talks about the involvement of participants, cancer research and the need for genomic data diversity.
The pandemic has caused many people to die alone in hospital intensive care units - whilst others have died at home without the support and pain relief they needed. The Lancet Commission on the Value of Death is calling for a radical change in how we approach death. Co-author Dr Libby Sallnow explains what makes a good death, and palliative care consultant Dr M R Rajagopal shares how communities have transformed palliative care in Kerala, India. Mixed messaging around Covid vaccines for pregnant women have resulted in a low uptake, leaving mothers and babies at risk of infection and serious complications. Dr Sarah Stock, an Honorary Consultant and Subspecialist in Maternal and Fetal Medicine at the University of Edinburgh, reassures us that vaccines are safe in pregnancy. Following the Spotify misinformation row, Marnie Chesterton asks how should streaming platforms respond to false claims about Covid-19? Professor Matt Fox from Boston University says they have a responsibility to tackle misinformation but warns that censorship may do more harm than good. Also, how a new scan is revealing hidden lung damage in long Covid, and should our chocolate treats come with picture warnings of clogged arteries? Presenter: Marnie Chesterton Producer: Paula McGrath and Samara Linton (Picture: A senior woman being comforted by a doctor in a hospice. Photo credit: Pornpak Khunatorn/Getty Images.)
Our Editor-in-Chief Sue Yom hosts a discussion of national workforce surveys with Dr. Shaun Loewen, Clinical Associate Professor and Director of the University of Calgary Radiation Oncology Residency Training Program and Chair of the Canadian Association of Radiation Oncology (CARO) Human Resources Committee, and Dr. Nicola Thorp, Consultant in Clinical Oncology at the Clatterbridge Cancer Centre and Honorary Consultant at the Christie Hospital, and Medical Director of Professional Practice in Clinical Oncology at the Royal College of Radiologists (RCR) in the U.K.
Air pollution kills an estimated seven million people worldwide every year. World Health Organisation data shows that 9 out of 10 people breathe air that exceeds WHO guideline limits. And UK air pollution is 'linked to 40,000 early deaths a year' The podcast is in support of the International Day of Clean Air for blue skies. This episode explores the links between air pollution and transport. Featuring on the podcast: Andrea Lee - Campaigns and Policy Manager, Clean Air at Client Earth and Dr Suzanne Bartington from the University of Birmingham who is a Clinical Research Fellow in Environmental Health and Honorary Consultant in Public Health. In 2013 Ella Addo-Kissi-Deborah died at the age of 9. In the Coroner - Philip Barlow's - report he highlighted the medical cause of death as: 1a) Acute respiratory failure 1b) Severe asthma 1c) Air pollution exposure Ella is the first person in the UK to have air pollution listed as the cause of death on their death certificate; the implications of this are explored in the podcast. About the speakers: Andrea is the Clean Air Campaigns and Policy Manager for environmental law organisation ClientEarth, which has successfully challenged the UK Government in court for failing to meet legal levels of air pollution. Andrea has worked in sustainability and sustainable transport projects for more than 15 years and has been part of the clean air team at ClientEarth since 2013. At ClientEarth, she campaigns for a national network of Clean Air Zones to urgently reduce illegal levels of air pollution, alongside measures to provide help and support for people and businesses to quickly move on to cleaner forms of transport. She is also campaigning for new clean air legislation to better protect people's health and ensure that the UK meets stronger World Health Organization guideline levels for air pollution by 2030 at the latest. A strong believer in the importance of collaborating and bringing out different voices, Andrea also coordinates the Healthy Air Campaign. Together this national coalition of health, transport and environmental NGOs is advocating for more ambitious action at all levels of government to tackle air pollution.” Dr Suzanne Bartington (Principal Investigator) is a Clinical Research Fellow in Environmental Health in the Institute of Applied Health Research and Honorary Consultant in Public Health at Public Health England. Her research portfolio extends across three core themes: (i) health and environmental impacts of ambient and indoor air pollution; (ii) sustainable transport mobilities specifically links between active travel infrastructure and health; (ii) environmental public policy formulation, implementation and evaluation. Suzanne has cross-cutting interests in development of new methods for monitoring, analysing and modelling impacts of air quality and application of mixed-methods approaches for public health intervention evaluation. Existing research includes studies funded by the Natural Environmental Research Council (NERC), National Institute for Health Research (NIHR) Public Health Research and Engineering and Physical Sciences Research Council (EPSRC).
Air pollution kills an estimated seven million people worldwide every year. World Health Organisation data shows that 9 out of 10 people breathe air that exceeds WHO guideline limits. And UK air pollution is 'linked to 40,000 early deaths a year'The podcast is in support of the International Day of Clean Air for blue skies. This episode explores the links between air pollution and transport. Featuring on the podcast: Andrea Lee - Campaigns and Policy Manager, Clean Air at Client Earth and Dr Suzanne Bartington from the University of Birmingham who is a Clinical Research Fellow in Environmental Health and Honorary Consultant in Public Health.In 2013 Ella Addo-Kissi-Deborah died at the age of 9. In the Coroner - Philip Barlow's - report he highlighted the medical cause of death as:1a) Acute respiratory failure 1b) Severe asthma 1c) Air pollution exposure Ella is the first person in the UK to have air pollution listed as the cause of death on their death certificate; the implications of this are explored in the podcast.About the speakers: Andrea is the Clean Air Campaigns and Policy Manager for environmental law organisation ClientEarth, which has successfully challenged the UK Government in court for failing to meet legal levels of air pollution. Andrea has worked in sustainability and sustainable transport projects for more than 15 years and has been part of the clean air team at ClientEarth since 2013. At ClientEarth, she campaigns for a national network of Clean Air Zones to urgently reduce illegal levels of air pollution, alongside measures to provide help and support for people and businesses to quickly move on to cleaner forms of transport. She is also campaigning for new clean air legislation to better protect people's health and ensure that the UK meets stronger World Health Organization guideline levels for air pollution by 2030 at the latest. A strong believer in the importance of collaborating and bringing out different voices, Andrea also coordinates the Healthy Air Campaign. Together this national coalition of health, transport and environmental NGOs is advocating for more ambitious action at all levels of government to tackle air pollution.”Dr Suzanne Bartington (Principal Investigator) is a Clinical Research Fellow in Environmental Health in the Institute of Applied Health Research and Honorary Consultant in Public Health at Public Health England. Her research portfolio extends across three core themes: (i) health and environmental impacts of ambient and indoor air pollution; (ii) sustainable transport mobilities specifically links between active travel infrastructure and health; (ii) environmental public policy formulation, implementation and evaluation. Suzanne has cross-cutting interests in development of new methods for monitoring, analysing and modelling impacts of air quality and application of mixed-methods approaches for public health intervention evaluation. Existing research includes studies funded by the Natural Environmental Research Council (NERC), National Institute for Health Research (NIHR) Public Health Research and Engineering and Physical Sciences Research Council (EPSRC).
Air pollution kills an estimated seven million people worldwide every year. World Health Organisation data shows that 9 out of 10 people breathe air that exceeds WHO guideline limits. And UK air pollution is 'linked to 40,000 early deaths a year' The podcast is in support of the International Day of Clean Air for blue skies. This episode explores the links between air pollution and transport. Featuring on the podcast: Andrea Lee - Campaigns and Policy Manager, Clean Air at Client Earth and Dr Suzanne Bartington from the University of Birmingham who is a Clinical Research Fellow in Environmental Health and Honorary Consultant in Public Health. In 2013 Ella Addo-Kissi-Deborah died at the age of 9. In the Coroner - Philip Barlow's - report he highlighted the medical cause of death as: 1a) Acute respiratory failure 1b) Severe asthma 1c) Air pollution exposure Ella is the first person in the UK to have air pollution listed as the cause of death on their death certificate; the implications of this are explored in the podcast. About the speakers: Andrea is the Clean Air Campaigns and Policy Manager for environmental law organisation ClientEarth, which has successfully challenged the UK Government in court for failing to meet legal levels of air pollution. Andrea has worked in sustainability and sustainable transport projects for more than 15 years and has been part of the clean air team at ClientEarth since 2013. At ClientEarth, she campaigns for a national network of Clean Air Zones to urgently reduce illegal levels of air pollution, alongside measures to provide help and support for people and businesses to quickly move on to cleaner forms of transport. She is also campaigning for new clean air legislation to better protect people's health and ensure that the UK meets stronger World Health Organization guideline levels for air pollution by 2030 at the latest. A strong believer in the importance of collaborating and bringing out different voices, Andrea also coordinates the Healthy Air Campaign. Together this national coalition of health, transport and environmental NGOs is advocating for more ambitious action at all levels of government to tackle air pollution.” Dr Suzanne Bartington (Principal Investigator) is a Clinical Research Fellow in Environmental Health in the Institute of Applied Health Research and Honorary Consultant in Public Health at Public Health England. Her research portfolio extends across three core themes: (i) health and environmental impacts of ambient and indoor air pollution; (ii) sustainable transport mobilities specifically links between active travel infrastructure and health; (ii) environmental public policy formulation, implementation and evaluation. Suzanne has cross-cutting interests in development of new methods for monitoring, analysing and modelling impacts of air quality and application of mixed-methods approaches for public health intervention evaluation. Existing research includes studies funded by the Natural Environmental Research Council (NERC), National Institute for Health Research (NIHR) Public Health Research and Engineering and Physical Sciences Research Council (EPSRC).
For many Long COVID patients the debilitating long-term symptoms they experience emerged after what, at first, appeared to be a mild COVID-19 infection. Professor David Strain, Senior Clinical Lecturer at University of Exeter Medical School and Honorary Consultant in Medicine, speaks to Patrick about the patterns he saw emerge while working on the frontline of the pandemic. From the first time David attended a meeting about COVID-19, at a 3am webinar broadcast from China, to working with Sano to help identify the genetic markers of Long COVID, they discuss the still emerging impact of the condition, from the first use of the term 'Long COVID' in May 2020, up until today.
For many Long COVID patients the debilitating long-term symptoms they experience emerged after what, at first, appeared to be a mild COVID-19 infection. Professor David Strain, Senior Clinical Lecturer at University of Exeter Medical School and Honorary Consultant in Medicine, speaks to Patrick about the patterns he saw emerge while working on the frontline of the pandemic. From the first time David attended a meeting about COVID-19, at a 3am webinar broadcast from China, to working with Sano to help identify the genetic markers of Long COVID, they discuss the still emerging impact of the condition, from the first use of the term 'Long COVID' in May 2020, up until today.
This piece focuses on iDelirium; The International Federation of Delirium Societies on world delirium day. As well as considering this difficult condition the conversation asks what the latest research shows us and how things could improve both for patients and practitioners. For more detail check out their website here: http://www.idelirium.org/ Presented by Desiree Chappell and Monty Mythen with their guests Heidi L. Lindroth, Senior Associate Consultant Nurse Scientist, Nursing Research Division Critical Care Nurse, Gideon Caplan, Director, Geriatric Medicine, Prince of Wales Hospital, Alasdair Macclullich, Professor of Geriatric Medicine, Honorary Consultant in Geriatric Medicine, Edinburgh, Delirium Research Group, Rakesh C. Arora, Co-Founder of IDelirium, Professor and Head of Cardiac Surgery and Cardiac Critical Care at Max Rady College of Medicine - University of Manitoba, Canada.
This week regular guest host Dr Anna Volkmer talks with the joint co-ordinating editors of the Cochrane Dementia Group. Listen to hear about the work of Cochrane, how they support evidence-informed decision making in healthcare, their work on undertaking systematic reviews and how you could become involved. This weeks guests are: Dr Terry Quinn, Clinical Senior Lecturer, Honorary Consultant and Joint co-ordinating editor of Cochrane Dementia Group. Terry is a clinician working in stroke and older adult services in Glasgow is also the national lead for ageing research in Scotland. Dr Jenny McCleery, Consultant Psychiatrist & Joint co-ordinating editor of Cochrane who describes herself as first, and foremost a Clinician. In her day-job she works as part of a community team for Older Adults at Oxfordshire Health NHS Foundation Trust. Cochrane Dementia and Cognitive Improvement Group, is part of Cochrane's Mental Health and Neuroscience Network. They aim is to provide the highest quality evidence about the care and medical treatment of people with dementia, delirium and other cognitive disorders, and about the diagnosis and prevention of these disorders. This is done through undertaking systematic reviews addressing questions which are important to patients, their families, and healthcare professionals from all disciplines. _________________________ You can read more about the scope of Cochrane Dementia and their work here: https://dementia.cochrane.org/our-work A transcript of this podcast is also available here https://www.dementiaresearcher.nihr.ac.uk/podcast-cochrane-dementia-and-cognitive-improvement-group Dr Terry Quinn Bio https://www.dementiaresearcher.nihr.ac.uk/profile-dr-terry-quinn/ Dr Jenny McCleery Bio https://www.dementiaresearcher.nihr.ac.uk/profile-dr-jenny-mccleery/ _________________________ Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode. Register on our website to receive your weekly bulletin, and to access more great content – blogs, science, career support + much more https://www.dementiaresearcher.nihr.ac.uk This podcast is brought to you in association with Alzheimer's Research UK and Alzheimer's Society, who we thank for their ongoing support.
Prof James Spicer is Professor of Experimental Cancer Medicine at King's College London and Honorary Consultant in Medical Oncology at GSTT. Professor Spicer runs the phase 1 trials programme at King's Health Partners and leads the King's Experimental Cancer Medicine Centre. His research focuses on the development of new cancer drugs and the care of patients with lung cancer with a special focus on novel immunotherapies. In this episode we ask him about: His career Oncology Research Advice for medical students and young doctors For comments, collaboration or feedback, contact us via email or Twitter. Email: medspirepodcast@gmail.com Twitter: @medspirepodcast
In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Emma Crosbie to discuss urine cytology in detection of endometrial cancer. Dr. Crosbie is an NIHR Advanced Fellow, Professor and Honorary Consultant in Gynaecological Oncology at the University of Manchester. Her research focuses on screening, prevention and early detection of gynaecological cancer. Highlights: • Current diagnostics for endometrial cancer are poorly tolerated by some, painful for others and unnecessary for most because only 5-10% of women with postmenopausal bleeding have endometrial cancer • This proof-of-concept study showed that endometrial cancer cells can be collected from the urogenital tract using non-invasive sampling technologies and detected by cytology • If confirmed in larger studies, this concept could form the basis of a simple, pain-free, easily administered test with potential for rapid, same day results to triage women for urgent investigation of suspected endometrial cancer, whilst safely reassuring healthy women • Such a test could substantially reduce the psychological, physical and financial burden of the current diagnostic pathway for endometrial cancer Emma Crosbie (@ProfEmmaCrosbie / @ECTeamSMH G25 / @ManchesterBRC / @UoMDCS / @MCRCNews / @FBMH_UoM / @MFT_SMH / @MFT_Research)
In this weeks podcast we discuss accessing HIV services during the pandemic and thereafter. Following on from our online discussion, we brought your questions to the panel to find out more on the issues that affect people living with HIV. As services adapted to the Covid-19 pandemic, many services changed to telephone and online appointments. You can find a full list of resources and support organisations in our show notes below. We hope you enjoy the show. Dr Stuart Flanagan is a Consultant in GU/HIV & Blood Borne Virus (BBV) Medicine at CNWL Trust's Mortimer Market Centre in Central London and Honorary Consultant at University College London Hospital. He is the Viral Hepatitis Lead for CNWL Trust. Stuart was an NIHR Clinical Research Fellow in Hepatology on the HepFREE study (testing for HBV and HCV in Primary care), which was published in Jan 2019 in the Lancet Gastro & Hep. He is chair of the BASHH HIV/BBV Special interest Group and the organising committee for the annual BASHH HIV Masterclass conference. Stuart has been a medical broadcaster for the BBC (BBC Radio 1 Surgery, CBBC's Newsround, BBC Breakfast). He wrote and presented a BBC Radio 4 documentary on antimicrobial resistance The Path Of Least Resistance, available to listen to via BBC iPlayer. Dr Richard Ma is a GP principal in London and NIHR Doctoral Research Fellow at Imperial College London. He has a research interest in delivery of sexual and reproductive health in primary care. His current research focuses on equity and impact of contraceptive provision in general practice. He has held positions including: member of RCGP's Sex Drugs and Blood Borne Virus Group, National Chlamydia Screening Advisory Group, expert member on NICE Guidelines on Preventing Sexually Transmitted Infections and under-18 conceptions and more recently expert member for NICE Quality Standards Advisory Committee on Contraception and NICE Scholar. He frequently writes and lectures on all matters related to sexual health/HIV and campaigns for better experience for LGBTQ+ patients in general practice. Most recently, he has been one of the founding members of #PrideRCGP programme, set up to improve experiences and well-being of LGBTQ+ community of peers and patients. Shaun Watson has worked in and around HIV since 1989 initially as an HIV link nurse in Hull (ensuring that healthcare professionals were educated and people living with HIV received appropriate care) and a volunteer counsellor at AIDS Action. Since 2005 I have worked as a community HIV clinical nurse specialist in central London and Chair of the National HIV Nurses Association for the past 4 years. Dr Nicola Mackie is a Consultant Physician and Clinical Director for HIV at Imperial College Healthcare NHS Trust. Her research was in the field of HIV-1 drug resistance and she runs the weekly Virtual Clinic. Although her main interest is clinical work, she is involved with writing national guidelines; examining for dipHIV and teaching for BASHH and EACS. She is a Trustee of the British HIV Association and a member of SWIFT (Supporting Women with HIV Information Network). Resources & support organisations The Mortimer Market Centre - https://www.shl.uk/clinic/mortimer-market-centre Jefferiss Wing Sexual Health - https://www.imperial.nhs.uk/our-services/sexual-health-and-hiv Positively UK podcasts https://positivelyuk.org/lgbt-podcast/ Dean Street Sexual Health https://dean.st/ --- Send in a voice message: https://anchor.fm/positivelyuk/message
This piece focuses on iDelirium; The International Federation of Delirium Societies on world delirium day. As well as considering this difficult condition the conversation asks what the latest research shows us and how things could improve both for patients and practitioners. For more detail check out their website here: http://www.idelirium.org/ Presented by Desiree Chappell and Monty Mythen with their guests Heidi L. Lindroth, Senior Associate Consultant Nurse Scientist, Nursing Research Division Critical Care Nurse, Gideon Caplan, Director, Geriatric Medicine, Prince of Wales Hospital, Alasdair Macclullich, Professor of Geriatric Medicine, Honorary Consultant in Geriatric Medicine, Edinburgh, Delirium Research Group, Rakesh C. Arora, Co-Founder of IDelirium, Professor and Head of Cardiac Surgery and Cardiac Critical Care at Max Rady College of Medicine - University of Manitoba, Canada.
The Beat podcast is designed for healthcare professionals and is brought to you by Nutricia. In this four-part miniseries The Beat focuses on epilepsy and the options for managing uncontrolled seizures when medication doesn't work. In this episode, Specialist Ketogenic Dietitian, Susan Wood, at Matthew's Friends Clinics, discusses the history of anti-seizure medications, their potential side effects and risks of uncontrolled seizures with Professor Helen Cross OBE. Professor Helen is The Prince of Wales's Chair of Childhood Epilepsy and Head of the Developmental Neuroscience Programme at UCL-Great Ormond Street Institute of Child Health, Honorary Consultant in Paediatric Neurology Great Ormond Street Hospital for Children NHS Foundation Trust, London and Young Epilepsy, Lingfield, UK.
In this episode we are joined by Dr Saira Ghafur, who is the Lead for Digital Health at the Institute of Global Health Innovation. Saira has co-founded healthcare innovation companies, and also works as an Honorary Consultant in Respiratory Medicine. Saira has previously worked at NHS England as the National Medical Director's Clinical Fellow, and also as a Harkness Fellow in Health Policy at the Commonwealth Fund. We discuss evidence generation in digital health, how healthcare policy underpins healthcare innovation and also about the value of mentors in creating a career path in this space. Find out more about the RSM digital council: http://rsm.ac/dhsectionpodcast. Follow us: #RSMdigihealth
St Emlyn's three professors, Carley, Body and Horner* critically appraise the Press Release regarding Dexamethasone in the treatment of COVID-19. What does this mean for the future of Evidence Based Medicine? Can we really start using a medication when the trial hasn't been peer reviewed and the full dataset not released? The blog post by Josh Farkas, that is mentioned in the podcast, is here. *Professor Simon Carley, Professor of Emergency Medicine at Manchester Metropolitan University and a Consultant in Adult and Paediatric Emergency Medicine at Manchester Foundation Trust, Professor Rick Body Professor of Emergency Medicine in Manchester and Honorary Consultant in Emergency Medicine at Manchester Foundation Trust. Professor Dan Horner, Professor of Emergency Medicine of the Royal College of Emergency Medicine and Consultant in Emergency Medicine and Intensive Care at Salford Royal NHS Foundation Trust.
Prof. Sam McConkey is a doctor and researcher specializing in the prevention and control of infectious diseases. Currently he is Associate Professor and Head of the Department of International Health and Tropical Medicine at the Royal College of Surgeons in Ireland. He is also a Consultant in General Medicine, Tropical Medicine and Infectious Diseases at Beaumont Hospital Dublin. Previously Prof. McConkey was a Research Fellow in Infectious Disease at Washington University School of Medicine in St. Louis, Missouri and an Honorary Consultant in Infectious Diseases at Oxford Radcliffe Trust. Show Notes: https://sigmanutrition.com/episode332/
In this week's podcast, we ran the second of our coronavirus Q&A specials, with Dr Chi Eziefula taking your questions on Covid-19. Dr Chi is Senior Lecturer in Infection at Brighton and Sussex Medical School (run jointly by the Universities of Brighton and Sussex) and an Honorary Consultant in Infectious Diseases and Microbiology at Brighton and Sussex University Hospitals NHS Trust. You can subscribe to this podcast via Spotify, Apple Podcasts, TuneIn and most other podcast apps - just search University of Brighton. If you want to get in touch, email podcasts@brighton.ac.uk.
In our first (pilot) episode we talk with Professor Bill Newman from Manchester about Rare opportunities and how will the 100, 000 Genomes Project change health care?Professor Bill Newman is Professor of Translational Genomic Medicine in The Manchester Centre for Genomic Medicine at the University of Manchester and Honorary Consultant at Manchester University NHS Foundation Trust. He is also Director of the Greater Manchester Genomic Medicine Centre for the 100,000 Genomes Project.Our RARE/D conversations are hosted by Nichola Garde and Mariangels Ferrer, and aim to stimulate and capture public conversation about one of the biggest changes in how we think about health – what does it mean to have a rare disease and how we all may become “RARE” when genomics becomes part of mainstream healthcare. This project will focus on the psychological, ethical and economic debates and in turn show how social science is helping to shape the health care of the future.
Dr Christopher Lamb, Clinical Intermediate Fellow at Newcastle University and Honorary Consultant in Gastroenterology at the Newcastle upon Tyne Hospitals NHS Foundation Trust discusses the BSG guidelines on the management of inflammatory bowel disease in adults with Associate Editor of GUT Dr Philip Smith. Read the article: https://gut.bmj.com/content/68/Suppl_3/s1
Involving patients in researching their own condition – it seems logical, so why is it not more common? Listen as Paul Evans discusses the benefits, challenges and future of including patients as research partners. With professionals, patients and policy leaders. This edition was facilitated by the British Pain Society and recorded at their Annual Scientific Meeting 2019. In this edition of Airing Pain, Paul Evans investigates the potential for patients to play an integral role in research, alongside the professionals. Through discussions with patients John and Mark both of whom are part of research groups, he sheds light on the importance of patients shaping the research and treatment of their own condition. From patients being included in directing their own treatment plan to actually influencing the direction of original scientific research, there are many benefits to their involvement. Louise Trewern, a member of the BPS Patient Liaison Committee, speaks of her journey from coming off opioids to working with Doctors in order to help others in similar situations. She highlights need to break down the ‘language’ barrier between professionals and patients. Margaret Whitehead and Julie Ashworth explore how the BPS and the University of Keele, respectively, are encouraging patient involvement. Specifically, Julie talks about the University of Keele’s efforts to improve primary care with their programme PROMPPT. Finally, Paul discusses the future work required to challenge the “doctor knows better” attitude excluding patients from influencing the treatment of their condition for future generations. Contributors: John Norton, patient Mark Farmer, patient Louise Trewern, member of the BPS Patient Liaison Committee Margaret Whitehead, past co-chair of the BPS Patient Liaison Committee Julie Ashworth, Senior Lecturer University of Keele and Honorary Consultant at the Community Pain Service with Midlands Partnership Foundation Trust. More information: INVOLVE, National Institute for Health Research, https://www.invo.org.uk/ National Voices, https://www.nationalvoices.org.uk/ Citizen Science Association, https://www.citizenscience.org/ BPS Patient Liaison Committee https://www.britishpainsociety.org/about/bps-committees/ Proactive clinical Review of patients taking Opioid Medicines long-term for persistent Pain led by clinical Pharmacists in primary care Teams (PROMPPT) https://www.promppt.co.uk/.
Mark McPhail is a senior lecturer and consultant in liver critical care at Kings College London. He trained in physics and medicine in Glasgow and following medical school he trained in Oxford, Southampton and London in gastroenterology, hepatology, general internal medicine and intensive care medicine. His research interests include outcome prediction, statistical methods, metabonomics and immunometabolism in liver failure syndromes. Nazir Lone is a Senior Clinical Lecturer in Critical Care and Honorary Consultant in Critical Care at the Royal Infirmary of Edinburgh. His programme of research focuses on health services research and health care quality improvement for acutely ill patients. His research aims to directly improve the quality of care for patients before, during and after an episode of critical illness through rigorously conducted research and engagement with key stakeholders. He has a particular research interest in epidemiological methods and using linked ‘big’ data.
Dr Simon Lord presents a clinical study to understand the effect of metformin - one of the most commonly prescribed treatments worldwide for diabetes - on breast cancer metabolism. Dr Simon Lord is a Senior Clinical Researcher in Experimental Cancer Therapeutics and Honorary Consultant in Medical Oncology at the University of Oxford.
Dr Simon Lord presents a clinical study to understand the effect of metformin - one of the most commonly prescribed treatments worldwide for diabetes - on breast cancer metabolism. Dr Simon Lord is a Senior Clinical Researcher in Experimental Cancer Therapeutics and Honorary Consultant in Medical Oncology at the University of Oxford.
Point-of-Care Ultrasound (POCUS) is becoming a global movement. Listen to Dr. Modele Olowoyeye, PhD, POCUS Certified, Radiologist at the College of Medicine at the University of Lagos, Senior Lecturer, Honorary Consultant at Lagos University Teaching Hospital, talk about the state of POCUS and the challenges and the opportunities for it in Lagos, Nigeria.
2pm ET / 1pm CT / 12pm MT / 11am PT (Outside US: Dial 00 + 1 + 714-464-4891) Viki Winterton interviews Dr. Jean Farish! Dr. Jean Farish is a Best-Selling Award-Winning Author, Transformational Author Experience (TAE) Award Winner, Educator, and Life Care Coach. She is the Founder and CEO of Life Care Wellness PEP For Angels, Inc. (LCWPEP), a non-profit organization to “enrich lives and serve our community” with special emphasis on serving hospitalized children. Dr. Farish earned her Ph.D. (Rehabilitation), MS (Rehabilitation Counseling) and BA (Psychology) and is a Certified Rehabilitation Counselor (CRC). She is a former higher education administrator where she served as Department Chair and Professor at Jackson State University. Her most life-changing transformative experience was a six-month journey in Penang where she served as Honorary Consultant in the Division of Industry and Community Engagement at Universiti Sains Malaysia. Dr. Farish and Viki Winterton have co-authored the new #1 International Bestseller, My Joy Journal, which is full of motivational texts and positive words and is aimed towards children and youth. It is a comprehensive, multi-purpose journal that can be utilized in many different ways to develop emotional intelligence. It includes space for creating art, writing down thoughts, and collecting photos to mentally stimulate young children and help them express themselves. Teachers and parents can use this new book alike as an educational resource. Also geared towards children who are cancer survivors, My Joy Journal can help cancer-surviving children articulate their experience and start a healing journey towards the future.
David Alexander McGowan was Professor of Oral Surgery and Honorary Consultant in Oral Surgery to the Greater Glasgow Health Board, 1977 to 1999. McGowan graduated from Queen's University, Belfast, in 1961. He became a lecturer in Oral Surgery at the London Hospital Medical College's Dental School in 1968, and was appointed Senior Lecturer the following year. He was Dean of the Dental Faculty of the Royal College of Physicians and Surgeons of Glasgow, 1989 to 1992, and Chairman of the National Dental Advisory Committee for Scotland from 1995 to 1999. He was Chairman of the Dental Committee of the Scottish Council for Postgraduate Medical Education 1979-90, Dean of the Glasgow Dental School from 1989-94, first Dean of the Dental Faculty of the Royal College of Physicians and Surgeons of Glasgow, 1989-92, Vice President of the General Dental Council 1994-99, Chairman of the National Dental Advisory Committee for Scotland 1995-99, Senate Assessor on the University Court 1994-99, and served on the EU Advisory Committee on Dental Education 1989-2002. Professor McGowan was awarded University medals from the Universities of Helsinki and Malta and the Bulgarian Medical Academy, and was founder Editor of Dental History Magazine 2007-11.
Thank you for listening to this podcast, where Frontline Gastroenterology Trainee Editor Dr Manmeet Matharoo talks to Dr Gautam Mehta, a Honorary Consultant and Senior Lecturer in Hepatology at UCL, with interests in cirrhosis, acute-on-chronic liver failure and alcohol-related liver disease. Gautam also an interest in Digital Health - starting one of the first secondary prevention m-Health trials in the UK @alcochange Next month's twitter debate will be on the 8th June and co-hosted with the British Society of Gastroenterology @BritSocGastro. The debate is entitled: “With the current capacity crisis in the NHS, what is the future of specialist endoscopy?” and will be led by Professor Pradeep Bhandari (@gastro3570) a Consultant Physician and Gastroenterologist at Portsmouth Hospital NHS Trust, and winner of both the Hopkins Endoscopy Award and Crystal Award for his contributions to the field of gastroenterology” Please follow #FGDebate and #BSG2016
Janet Richardson is Professor of Health Service Research in the Faculty of Health, Education and Society at Plymouth University, and an Honorary Consultant in Public Health with NHS Plymouth. In 2011 she did the first Health Impact Assessment on a Transition initiative, looking at Transition Town Totnes.
Prof John Yarnold talks to ecancertv at the UK's National Cancer Research Institute ( NCRI ) 2013 meeting about optimial radiotherapy for breast cancer. Breast cancer is as sensitive to radiation fraction size as normal tissues, 10-year follow-up of clinical trials, including the UK START trials, has shown. This means it makes sense to give early breast tumours fewer, larger doses of radiation, rather than more, smaller doses. The result has been to switch from a standard five-week schedule of 25 fractions to a more convenient three-week schedule delivering 15 fractions of 2.7 Gy. Current 15-fraction schedules are standard of care for local-regional radiotherapy in the UK, but 15- or 16-fraction regimens are unlikely to represent the lower limit. It is now important to find out if there is wide variation between breast cancers in their sensitivity to different levels of radiation. If there is a lot of variation between cancers, it highlights the need to identify tests to exploit this variation for the benefit of future patients. By the end of this decade, research could bring about a regimen of local-regional radiotherapy with as few as five fractions for women with early breast cancer. John Yarnold is Professor of Clinical Oncology at The Institute of Cancer Research, London, and Honorary Consultant at the Royal Marsden NHS Foundation Trust.
© 2020-2025 Ivy Podcast Discovery LLC
